OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 06, 2009

Cochrane Collaboration review/commentaries: Interventions for psychosexual dysfunction in women treated for gyn malignancy



Comments from Clinical Raters
Gynecology
A very useful review that confirms the need for proper randomised studies to answer this important question. My misgivings on the apparent lumping of all gynaecological malignancies together is that it creates an obviously flawed impression that sexual problems after treatment of gynaecological cancer of any kind might have a common solution.
Oncology - General
I was surprised to find that there was any evidence at all from randomised studies that addressed questions in this important area. The authors rightly draw attention to the paucity of evidence and its poor quality. As interest increases in what is now called cancer survivorship, we can anticipate an increasing need for solid evidence on which to base management for the complex difficulties experienced by patients successfully treated for cancer. This paper indicates that it is not going to be easy to assemble the necessary evidence.

Screening Tests Missing Early Signs of Ovarian Cancer - Oncology Nursing News



Screening Tests Missing Early Signs of Ovarian Cancer - Oncology Nursing News

Comment:
S. Pniauskas

Please also, and importantly, reference the recently published early detection ovarian cancer clinical trial by Dr Jacobs from the U.K.. Further, Dr Jacobs completed a study of 22,000 women over a decade ago with the same results. So, nothing has changed even after all of this time which is very sad. So much time has elapsed, so many deaths and sufferings. A coordinated international effort is needed badly and while new research is hopeful, our ovarian cancer communities have faced extreme dissapointments with even new and 'apparent' early detection tests of recent years. It would be seriously disconcerting to know that another decade may lapse without any definitive results. This does not take away from the goodwill and integrity of the research/ers, but a more effective and coordinated effort is needed.

Researchers Detail Chemotherapy's Damage to the Brain - URMC Press Room




NCI: Delving Into Possible Mechanisms for Chemobrain



NCI Cancer Bulletin for March 24, 2009 - National Cancer Institute

Time-related communication skills from the cancer patient perspective




Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer




Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a GOG group member treatment center: 1979-2001



High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid




Improved progression free and overall survival in advanced cancer as a result of a change in sugical paradigm



"PFS rates were 31% vs 14%"

Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?



Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.



"Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer."

Sunday, May 03, 2009

Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic application



Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?



Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound



Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treat



Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study.



Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.



Recall of and Reactions to a Surgeon Referral Letter for BRCA Genetic Counseling Among High-Risk Breast Cancer Patients.




Local surgical, ablative, and radiation treatment of metastases




Saturday, May 02, 2009

The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary.



The role of hepatocyte nuclear factor-1beta in the...[Int J

Identification of a Novel Kindred with Familial Pancreatitis and Pancreatic Cancer




Family history of various cancers and pancreatic cancer mortality in a large cohort. (BRCA 2/Lynch Syndromes?)



Repost from 2007: Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna | LIVESTRONG.COM



Note: We have since lost Carolyn.

Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna | LIVESTRONG.COM

Peutz-Jeghers Syndrome: eMedicine Gastroenterology updated Apr 2009



Peutz-Jeghers Syndrome: eMedicine Gastroenterology: "Almost 50% of patients with Peutz-Jeghers syndrome (PJS) develop and die from cancer by age 57 years. The mean age at first diagnosis of cancer is 42.9 years, /– 10.2 years.

* The cumulative risk for developing any cancers associated with Peutz-Jeghers syndrome (PJS) in patients aged 15–64 years is 93%.

* The cumulative risks of developing a particular cancer from ages 15-64 years are as follows: esophagus, 0.5%; stomach, 29%; small intestine, 13%; colon, 39%; pancreas, 36%; lung, 15%; testes, 9%; breast, 54%; uterus, 9%; ovary, 21%; and cervix, 10%."

post WHI: Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-o



Review Transition from acute to chronic postsurgical pain: risk factors and protective factors



However, a rarely appreciated fact is that every chronic pain was once acute.

Wrong Approach to Obesity Can Alienate Patients - Physicians can unintentionally de-motivate black patients



Editorial note: it takes a study to understand this?

"patients may respond unexpectedly if approached in a manner they perceive as disrespectful, condescending, emotionless, or non-supportive,' the authors write."

Friday, May 01, 2009

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis



Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis -- Tonelli et al., 10.1503/cmaj.090470 -- Canadian Medical Association Journal

Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating



abstract: The effect of symptom duration in epithelial ovarian cancer on prognostic factors



Webcasts - AACR



Webcasts: "More than 90 hours of selected Annual Meeting talks will be made available as free online webcasts approximately 10 business days* after the AACR 100th Annual Meeting 2009 and will remain accessible for two years. Sessions that are to be webcast will include audio and, if available, slides from the talks.

Note: Only individual talks within a session that AACR has received permission to webcast will be included. For example, if there are four talks in a session and only two speakers give their permission to be webcast, then only those two talks will be made available.

*The Opening Plenary and the Spotlight on Breakthroughs in Cancer Research session will both be available as webcasts approximately 24 hours after they conclude."

Multiple Regions Of Chromosome 8 Found To Be Associated With Different Cancers



this link above is previous research (2008) regarding chromosome 8q24 region and it's wider scope of impact:

The authors' analysis suggests that there may be five distinct subregions within 8q24, separated by sites of frequent recombination, and each associated with different types of cancer. The first subregion is associated with an increased risk of prostate cancer but not with risk of breast, colorectal, or ovarian cancer. The second is associated only with an increased risk of breast cancer. The third subregion is associated with the risk of prostate, colorectal and ovarian cancers, but not breast, and subregions four and five were associated with prostate cancer, but not with the other three malignancies.

"We have shown there are at least five independent loci within this gene desert with different associations with particular cancers," the authors write. "Further studies of the region may identify additional loci associated with specific cancers and possibly refine our understanding of the mechanisms underlying the associations reported here."

Beyond Associations: Colorectal Cancer Culprit Found